Background: Although more attention has been paid recently to B-cell immunity, assay for B-cell analysis has yet to be clinically applicable because, unlike T cell, a B-cell culture system has not been well established.
Methods: We attempted to develop an in vitro culture system for the proliferation and differentiation of peripheral B cells into plasma cells, and to analyze the action of everolimus (EVR), mycophenolic acid (MPA), and prednisolone (PRD).
Results: Using a three-step culture system, peripheral CD19 B cells could differentiate into plasma cells and produce IgG antibody. Activated B cells (CD19(hi)CD38(lo)IgD(-)), plasmablasts (CD19(hi)CD38(hi)IgD(-)), and plasma cells (CD19(lo/-)CD38(hi)IgD(-)) were observed as a main cell subset in step 1 (day 0-4), 2 (day 4-7), and 3 (day 7-10), respectively. IgG production on day 10 was significantly suppressed by EVR, MPA, and PRD, but not cyclosporine. Although both EVR and MPA inhibited B-cell proliferation and differentiation in step 1, EVR suppressed B-cell differentiation in step 2. Only a high concentration of PRD significantly inhibited B-cell proliferation, differentiation, and IgG production in step 3.
Conclusions: Although both MPA and EVR efficiently suppressed cell proliferation during the early phase of B-cell immune reaction, EVR could act in a later phase than MPA. PRD at a high concentration worked even in the last phase. An in vitro B-cell culture system would clarify the mode of drug action during B-cell differentiation and provide useful information on the effective selection or combination of immunosuppressive agents.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032219 | PMC |
http://dx.doi.org/10.1097/01.TP.0000441826.70687.f6 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!